Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Fertin Pharma A/S has 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 9 distinct examiners and 5 distinct art units. This distribution indicates that each of the 9 pending actions is being reviewed by a different individual, providing a wide range of perspectives on the company's applications.
PETRITSCH, AMANDA MICHELLE is the busiest examiner for the company, with 1 pending office action. The involvement of 5 distinct art units indicates that the company's pharmaceutical applications are being reviewed by several different specialized groups within the patent office. For a practitioner, this means that the company's biotechnology portfolio is technically diverse, requiring a prosecution strategy that can navigate the specific requirements of 5 different units. With 9 distinct examiners each handling 1 action, no single examiner's tendencies will dominate the current prosecution landscape. This spread across examiners and art units suggests a robust and varied approach to patenting within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| Double-patenting + other | 4 (44%) |
| Multi-statute (no §101) | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETRITSCH, AMANDA MICHELLE | 1 | 57.1% | +28.1% |
| VIGIL, TORIANA NICHOLE | 1 | 53.1% | +24.1% |
| BABSON, NICOLE PLOURDE | 1 | 46.6% | +33.1% |
| ARMSTRONG, SUSANNAH SIPPLE | 1 | 30.0% | +53.1% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| YU, HONG | 1 | 30.9% | +5.6% |
| PARK, HAEJIN S | 1 | 55.0% | +38.4% |
| JACOBSON, MICHELE LYNN | 1 | 28.0% | +32.9% |
| PHAN, DOAN THI-THUC | 1 | 42.7% | +47.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18608586 | ORALLY DISINTEGRATING NICOTINE TABLET FOR USE UNDER LIP | PARK, HAEJIN S | 44d overdue |
| 17857937 | Cannabinoid Lipid Premixture | JACOBSON, MICHELE LYNN | 30d |
| 18686557 | Multi-Layered Dextrose Tablets | ARMSTRONG, SUSANNAH SIPPLE | — |
| 17502322 | DEXTROSE TABLETS WITH IMPROVED MOUTHFEEL | PHAN, DOAN THI-THUC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18608586 | ORALLY DISINTEGRATING NICOTINE TABLET FOR USE UNDER LIP | PARK, HAEJIN S | 44d overdue |
| 18612007 | Carrier Systems For Cannabinoids | YOUNG, MICAH PAUL | 12d |
| 17857937 | Cannabinoid Lipid Premixture | JACOBSON, MICHELE LYNN | 30d |
| 19046728 | Oral Powder Mixture With Small Sized Particles | PETRITSCH, AMANDA MICHELLE | — |
| 18876619 | FLOWPACK WITH COMPOSITION FOR IMPROVED TASTE MASKING OF ACTIVES | VIGIL, TORIANA NICHOLE | — |
| 18883730 | ORALLY DISINTEGRATING NICOTINE TABLET WITH LOW AMOUNT OF FLAVOR | BABSON, NICOLE PLOURDE | — |
| 18686557 | Multi-Layered Dextrose Tablets | ARMSTRONG, SUSANNAH SIPPLE | — |
| 17502322 | DEXTROSE TABLETS WITH IMPROVED MOUTHFEEL | PHAN, DOAN THI-THUC | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1616 | 1 |
| 1618 | 1 |
| 1793 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19046728 | Oral Powder Mixture With Small Sized Particles | PETRITSCH, AMANDA MICHELLE | — | §103§112DP | Non-Final OA | — | Pending | Feb 06, 2025 |
| 18876619 | FLOWPACK WITH COMPOSITION FOR IMPROVED TASTE MASKING OF ACTIVES | VIGIL, TORIANA NICHOLE | — | §103DP | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18883730 | ORALLY DISINTEGRATING NICOTINE TABLET WITH LOW AMOUNT OF FLAVOR | BABSON, NICOLE PLOURDE | — | §102§103§112DP | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18686557 | Multi-Layered Dextrose Tablets | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §102§103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18612007 | Carrier Systems For Cannabinoids | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | 12d | Pending | Mar 21, 2024 |
| 18612256 | Cannabinoid Self-Emulsifying Systems | YU, HONG | 1614 | §103DP | Final Rejection | — | Pending | Mar 21, 2024 |
| 18608586 | ORALLY DISINTEGRATING NICOTINE TABLET FOR USE UNDER LIP | PARK, HAEJIN S | 1614 | §103§112Other | Final Rejection | 44d overdue | Pending | Mar 18, 2024 |
| 17857937 | Cannabinoid Lipid Premixture | JACOBSON, MICHELE LYNN | 1793 | §103 | Final Rejection | 30d | Pending | Jul 05, 2022 |
| 17502322 | DEXTROSE TABLETS WITH IMPROVED MOUTHFEEL | PHAN, DOAN THI-THUC | 1613 | §103§112 | Final Rejection | — | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial